# Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

> **NCT06326723** · PHASE1 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Daridorexant

## Key facts

- **NCT ID:** NCT06326723
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-04
- **Primary completion:** 2023-12-24
- **Final completion:** 2024-02-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06326723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06326723, "Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06326723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*